PATENT CLAIM ANALYSIS

Application Number: 15962837
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-11
Patent Classification: ["514", "235200"]

Abstract:
The present invention relates to the use of PAR1 antagonists, in particular of vorapaxar, of atopaxar and of 3-(2-chlorophenyl)-1-[4-(4-fluorobenzyl)piperazin-1-yl]propenone, or a pharmaceutically acceptable salt thereof, for preventing and/or treating pelvi-perineal functional pathological conditions, and more particularly painful bladder syndrome.

Claim (Index 14):
The method according to  claim 11 , wherein the pharmaceutical composition is administered in endovesical administration form.

Metadata:
- Claim Count in Document: 32.0
- Percentile: 91.0
- Lexical Diversity: 1.21277
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15101170', '15207718', '15007682', '13798248', '10817332']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7153112405981119
- 35 USC 102 Novelty (BERT): 0.6176666504400448
- Combined Prediction Score: 0.7055467815823052
- Mean Citation Score: 281.6683060000001
- Max Citation Score: 608.5480299999998
- Similarity Product: 461.0547097747354

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test